Protection From Influenza: Determining the Impact of Prior Infection

Influenza Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03004040
• Other study ID #: Protection from Influenza
• Status: Recruiting
• Phase: N/A
• First received: December 19, 2016
• Last updated: February 22, 2018
• Start date: December 2016
• Est. completion date: January 2019

Study information

• Verified date: February 2018
• Source: Health Sciences North Research Institute
• Contact: Amanda Axler, BSc.
• Phone: 7055237300
• Email: aaxler[@]hsnri.ca
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The investigators propose a unique methodology of studying infection and vaccination history and immune responses. As most studies in infection history are conducted on mice, limitations are inherent on their applicability to humans. A longitudinal comparison study following older adults (over the age of 65) hospitalized for influenza are followed through to their hospital discharge and vaccination in the following season. This will allow for the investigation of the course of infection, as well as impact on the response to vaccination.

Description:

Significance: This study will provide critical information on the best technique in vaccine candidate testing and improve influenza treatment approaches. The long-term goal of this research is to identify the T-cell responses that are surrogates (biomarkers) of serious complications of influenza in older adults and predict vaccine efficacy (prevention of influenza illness) and vaccine effectiveness (prevention of serious complications). Further, translating new insights into age-related immune dysfunction to the design of new influenza vaccines is critical to addressing this unmet need in the population aged 65 and older.

Innovation: The study will help in the validation of clinical tools and biomarkers as prognostic indicators of influenza illness severity in vaccinated older adults, point-of-care diagnostics that would direct other preventive strategies to reduce the impact of influenza illness in vaccinated older adults, and correlates of protection to evaluate the potential of new influenza vaccines to enhance protection against the serious complications of influenza illness. The investigators have established that GrzB activity and the IFNg: IL-10 ratio in influenza-stimulated PBMC correlate with protection against influenza, and preliminary data to show that low GrzB activity in influenza-stimulated PBMC correlates with more severe disease and higher levels of frailty. The innovations of this project are the established methods for developing correlates of protection, the clinical insights into how frailty affects immune-mediated protection against influenza, and the direct translation of this research to provide a reasonable method for primary care clinicians to estimate vaccine effectiveness in an individual older person. These results will translate to the practical design of clinical trials to evaluate the potential for new influenza vaccines to better protect against the serious complications of influenza and complement those based on antibody titers and/or clinical outcomes alone.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: January 2019
• Est. primary completion date: January 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

1. Written informed consent provided by the participant.

2. Age 65 years of age or older admitted to Health Sciences North with at least one the following:

• Laboratory confirmed influenza illness

• Acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

• Any respiratory or influenza-like symptoms (dyspnea, cough, sore throat, myalgia, arthralgia, fever, delirium/altered level of consciousness) that a test for influenza was negative.

3. Willing to receive influenza vaccination in the subsequent flu season

Exclusion Criteria:

1. Patients whose reason for hospital admission was unrelated to influenza or (for example patients admitted due to trauma, elective surgery, or patients who have an alternative diagnosis that is clearly not respiratory).

2. Chest x-ray positive for pneumonia.

3. Study participants who cannot be vaccinated due to previous severe reaction to influenza vaccine, egg, latex, or thimerosol allergies, or refusal of vaccination.

4. Immunosuppressive disorders or medications (including oral prednisone in doses >10 mg daily).

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• Flu Vaccine

Locations

Country	Name	City	State
Canada	Health Sciences North Research Institute	Sudbury	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Health Sciences North Research Institute	NOAMA NORTHERN ONTARIO ACADEMIC MEDICINE ASSOCIATION

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	High expression of CTL associated cytokines and granzymes in PBMC's are predictors of influenza infection severity.	PBMCs from adults hospitalized for laboratory confirmed influenza illness (LCII) will be collected at admission and 30 days post hospitalization. These samples will be matched with hospitalized non-LCII adult controls. T-cells will be isolated from whole blood samples and gene expression of IFNg, IL10 and GrzB will be measured and compared between time points and subjects. These levels do not have a separate unit of measure.	2 years
Secondary	Vaccination in previously infected individuals increases the protection provided by subsequent vaccination and will be higher than those receiving vaccination alone (with no previous infection)	Older adults hospitalized for influenza illness the previous season will be compared to matched, hospitalized older adults with influenza-like illness (non-LCII). PBMCs will be collected from each group, before receiving influenza vaccination and 4 weeks after vaccination. PBMCs will be challenged ex vivo with influenza virus and gene expression of CTL related genes will be measured and compared between each group.	2 years